新辅助化疗联合贝伐珠单抗治疗三阴性乳腺癌的效果及对癌组织PFTK1表达的影响

Therapeutic effect of neoadjuvant chemotherapy combined with bevacizumab on triple-negative breast cancer and its influence on PFTK1 expression in cancer tissue

目的探讨新辅助化疗联合抗血管内皮生长因子(VEGF)靶向治疗药物贝伐珠单抗治疗三阴性乳腺癌的效果及对癌组织细胞周期依赖性蛋白激酶1(PETK1)表达的影响。方法前瞻性研究。抽取2015年9月至2022年9月临汾市中心医院收治的三阴性乳腺癌患者80例,按照就诊顺序分为治疗组和对照组,每组40例。对照组采用多柔比星+环磷酰胺新辅助化疗方案治疗,治疗组在对照组治疗基础上加用贝伐珠单抗注射液。比较两组患者的治疗效果,比较两组治疗前后血清VEGF水平及病理组织标本中PETK1的表达情况,比较两组患者治疗期间不良反应发生情况。结果治疗组治疗总有效率(57.50%,23/40)高于对照组(30.00%,12/40),P<0.05。治疗后,两组血清VEGF-165、VEGF-121、VEGF-145水平均低于治疗前(P均<0.05),且治疗组血清VEGF-165、VEGF-121、VEGF-145水平低于对照组(P<0.05)。治疗前,两组病理组织标本PFTK1阳性表达率比较差异未见统计学意义(P>0.05);治疗后,治疗组复查中PFTK1阳性表达率(32.5%,13/40)低于对照组(57.5%,23/40),P<0.05。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论新辅助化疗联合抗VEGF靶向治疗药物贝伐珠单抗治疗三阴性乳腺癌的疗效较好,其作用机制可能通过抑制PFTK1的表达来降低血管新生因子,发挥抗肿瘤作用。

Objective To investigate the therapeutic effect of neoadjuvant chemotherapy combined with bevacizumab,an anti-vascular endothelial growth factor(anti-VEGF)targeting drug,on triple-negative breast cancer,and its influence on the expression of cyclin-dependent protein kinase 1(PFTK1).Methods This study was a prospective trail.Eighty patients with triple-negative breast cancer admitted to Linfen Central Hospital from September 2015 to September 2022 were selected,and they were divided into treatment group and control group according to the order of admission,with 40 patients in each group.The control group was treated by adriamycin combined with cyclophosphamide AC neoadjuvant chemotherapy regimen,while the treatment group received bevacizumab injection based on the treatment of the control group.The therapeutic effects of the two groups were compared.The preoperative and postoperative levels of serum VEGF expression,and the expression of PETK1 in pathological tissue samples were compared between the two groups.The incidence of adverse reaction during treatment were compared between the two groups.Results The total effective rate in the treatment group(57.50%,23/40)was higher than that in the control group(30.00%,12/40),P<0.05.After treatment,the levels of serum VEGF-165,VEGF-121 and VEGF-145 in both groups were lower than before treatment(all P<0.05),while the levels of serum VEGF-165,VEGF-121 and VEGF-145 in the treatment group were lower than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in the positive expression rate of PFTK1 in pathological tissue samples between the two groups(P>0.05).The positive expression rate of PFTK1 in the follow-up examination of the treatment group(32.5%,13/40)was lower than that in the control group(57.5%,23/40)after treatment(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Neoadjuvant chemotherapy combined with bevacizumab,an anti-VEGF targeting drug,has a good effect in the treatment of triple-negative breast cancer.The mechanism may be that it can reduce angiogenesis factors by inhibiting the expression of PFTK1 to counteract tumor.